Aurobindo Pharma unit receives USFDA warning letter

Aurobindo Pharma unit receives USFDA warning letter after inspection of its Telangana facility. The USFDA cited deficiencies in quality control and data integrity, demanding immediate corrective actions. Failure to address could delay US market approvals and impact exports, which contribute ~35% of Aurobindo’s revenue.

📊 STOCKS: $AUROPHARMA | 🏢 SECTOR: Pharma | #HIGHIMPACT #USFDA